Jia L, Gao Y, He Y, Hooper JD, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020;159:104992.
Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20:524–37.
Tu T, McQuaid TJ, Jacobson IM. HBV-induced carcinogenesis: mechanisms, correlation with viral suppression, and implications for treatment. Liver Int. 2025;45:e16202.
Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39:26–42.
Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review. Cells. 2022;11:741.
Ma M, Yi L, Pei Y, Zhang Q, Tong C, Zhao M, et al. USP26 as a hepatitis B virus-induced deubiquitinase primes hepatocellular carcinogenesis by epigenetic remodeling. Nat Commun. 2024;15:7856.
Wang Y, Zhao M, Zhao L, Geng Y, Li G, Chen L, et al. HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression. Cancer Res. 2023;83:1048–61.
Wang Y, Guan X, Lv F, Rong Y, Meng X, Tong Y, et al. HBx integration in diffuse large B-cell lymphoma inhibits Caspase-3-PARP related apoptosis. Tumour Virus Res. 2024;18:200290.
Huang FY, Wong DK, Seto WK, Mak LY, Cheung TT, Yuen MF. Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. Cell Death Discov. 2021;7:88.
He C, Qiu Y, Han P, Chen Y, Zhang L, Yuan Q, et al. ER stress regulating protein phosphatase 2A-B56gamma, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes. Cell Death Dis. 2018;9:762.
Dong J, Zhang R, Xia Y, Jiang X, Zhou K, Li J, et al. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC. Front Immunol. 2023;14:1142319.
Xiao C, Gong J, Jie Y, Liang W, Tai Y, Qin W, et al. E2F1-mediated up-regulation of NCAPG promotes hepatocellular carcinoma development by inhibiting pyroptosis. J Clin Transl Hepatol. 2024;12:25–35.
Zhao Q, Chen DP, Chen HD, Wang YZ, Shi W, Lu YT, et al. NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitate HBV-related acute-on-chronic liver failure. Hepatology. 2025;81:917–31.
Xie WH, Ding J, Xie XX, Yang XH, Wu XF, Chen ZX, et al. Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation. Inflamm Res. 2020;69:683–96.
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254–61.
Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol. 2008;4:176–85.
Yang Y, Wu J, Wang L, Ji G, Dang Y. Copper homeostasis and cuproptosis in health and disease. MedComm. 2024;5:e724.
Tang D, Kroemer G, Kang R. Targeting cuproplasia and cuproptosis in cancer. Nat Rev Clin Oncol. 2024;21:370–88.
Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22:102–13.
Rashed MN. The role of trace elements on hepatitis virus infections: a review. J Trace Elem Med Biol. 2011;25:181–7.
Zheng P, Zhou C, Lu L, Liu B, Ding Y. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res. 2022;41:271.
Kirubakaran S, Sureshkumar D, Chandrasekaran S. Tetrathiomolybdate and tetraselenotungstate as sulfur/selenium transfer reagents: applications in the synthesis of new thio/seleno sugars. Chem Rec. 2021;21:3076–86.
Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006;108:1388–94.
Scarl RT, Lawrence CM, Gordon HM, Nunemaker CS. STEAP4: its emerging role in metabolism and homeostasis of cellular iron and copper. J Endocrinol. 2017;234:R123–R34.
Ju MH, Jang EJ, Kang SH, Roh YH, Jeong JS, Han SH. Six-transmembrane epithelial antigen of prostate 4: an indicator of prognosis and tumor immunity in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:643–58.
Liao Y, Zhao J, Bulek K, Tang F, Chen X, Cai G, et al. Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis. Nat Commun. 2020;11:900.
Kim HY, Cho HK, Yoo SK, Cheong JH. Hepatic STAMP2 decreases hepatitis B virus X protein-associated metabolic deregulation. Exp Mol Med. 2012;44:622–32.
Che L, Du ZB, Wang WH, Wu JS, Han T, Chen YY, et al. Intracellular antibody targeting HBx suppresses invasion and metastasis in hepatitis B virus-related hepatocarcinogenesis via protein phosphatase 2A-B56gamma-mediated dephosphorylation of protein kinase B. Cell Prolif. 2022;55:e13304.
Du ZB, Wu XM, Han T, Cai YX, Qian B, Shen YS, et al. MALAT1 promotes malignancy of HBV-related hepatocellular carcinoma by regulating IGF2BP3-mediated nuclear-cytoplasmic shuttling. Int J Biol Sci. 2025;21:4942–60.
Lan Y, Qian B, Huang HY, Wang P, Li T, Yuan Q, et al. Hepatocyte-derived prostaglandin E2-modulated macrophage M1-type polarization via mTOR-NPC1 axis-regulated cholesterol transport from lysosomes to the endoplasmic reticulum in Hepatitis B Virus x protein-related nonalcoholic steatohepatitis. Int J Mol Sci. 2022;23:11660.
Liu YT, Chen L, Li SJ, Wang WY, Wang YY, Yang QC, et al. Dysregulated Wnt/beta-catenin signaling confers resistance to cuproptosis in cancer cells. Cell Death Differ. 2024;31:1452–66.
Zhang JF, Xiong HL, Cao JL, Wang SJ, Guo XR, Lin BY, et al. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. Theranostics. 2018;8:549–62.
Hou Z, Quan J. Hepatitis B virus X protein increases microRNA‑21 expression and accelerates the development of hepatoma via the phosphatase and tensin homolog/phosphoinositide 3‑kinase/protein kinase B signaling pathway. Mol Med Rep. 2017;15:3285–91.
Tang F, Zhang JN, Zhao XL, Xu LY, Ao H, Peng C. Unlocking the dual role of autophagy: a new strategy for treating lung cancer. J Pharm Anal. 2025;15:101098.
Kalyanaraman B. Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: challenges and opportunities in racial disparity and cancer outcome research. FASEB J. 2022;36:e22226.
Zoulim F, Chen PJ, Dandri M, Kennedy PT, Seeger C. Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome. J Hepatol. 2024;81:1087–99.
Liu W, Yao Q, Su X, Deng Y, Yang M, Peng B, et al. Molecular insights into Spindlin1-HBx interplay and its impact on HBV transcription from cccDNA minichromosome. Nat Commun. 2023;14:4663.
Wang Y, Chen Y, Zhang J, Yang Y, Fleishman JS, Wang Y, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updat. 2024;72:101018.
Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22:46.
Fang AP, Chen PY, Wang XY, Liu ZY, Zhang DM, Luo Y, et al. Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort. Int J Cancer. 2019;144:2823–32.
Liao Q, Deng J, Tong J, Gan Y, Hong W, Dong H, et al. p53 induces circFRMD4A to suppress cancer development through glycolytic reprogramming and cuproptosis. Mol Cell. 2025;85:132–49.e7.
Sun Z, Xu H, Lu G, Yang C, Gao X, Zhang J, et al. AKT1 phosphorylates FDX1 to promote cuproptosis resistance in triple-negative breast cancer. Adv Sci. 2025;12:e2408106.
Schollmeier A, Glitscher M, Hildt E. Relevance of HBx for Hepatitis B virus-associated pathogenesis. Int J Mol Sci. 2023;24:4964.
Yan Y, Wei Z, Zheng M, Lu M, Wang X. HBV and host metabolic crosstalk: Reprogramming pathways for viral replication and pathogenesis. Virol Sin. 2025;40:685–93.
Chen YY, Wang WH, Che L, Lan Y, Zhang LY, Zhan DL, et al. BNIP3L-dependent mitophagy promotes HBx-induced cancer stemness of hepatocellular carcinoma cells via glycolysis metabolism reprogramming. Cancers. 2020;12:655.
Lu K, Wijaya CS, Yao Q, Jin H, Feng L. Cuproplasia and cuproptosis, two sides of the coin. Cancer Commun. 2025;45:505–24.
Wang T, Cao Y, Zheng Q, Tu J, Zhou W, He J, et al. SENP1-Sirt3 signaling controls mitochondrial protein acetylation and metabolism. Mol Cell. 2019;75:823–34.e5.
Zhang J, Xiang H, Liu J, Chen Y, He RR, Liu B. Mitochondrial sirtuin 3: new emerging biological function and therapeutic target. Theranostics. 2020;10:8315–42.
Overmyer KA, Evans CR, Qi NR, Minogue CE, Carson JJ, Chermside-Scabbo CJ, et al. Maximal oxidative capacity during exercise is associated with skeletal muscle fuel selection and dynamic changes in mitochondrial protein acetylation. Cell Metab. 2015;21:468–78.
Tarin M, Babaie M, Eshghi H, Matin MM, Saljooghi AS. Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications. J Transl Med. 2023;21:745.
Jin J, Bai L, Wang D, Ding W, Cao Z, Yan P, et al. SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. EMBO Rep. 2023;24:e56052.
